Journal of Autism and Developmental Disorders

, Volume 37, Issue 2, pp 367–373

Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

  • Gahan J. Pandina
  • Cynthia A. Bossie
  • Eriene Youssef
  • Young Zhu
  • Fiona Dunbar
Original Paper

DOI: 10.1007/s10803-006-0234-7

Cite this article as:
Pandina, G.J., Bossie, C.A., Youssef, E. et al. J Autism Dev Disord (2007) 37: 367. doi:10.1007/s10803-006-0234-7

Abstract

Subgroup analysis of children (5–12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (= 27) or placebo (= 28); mean baseline ABC-I ( ± SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose ( ± SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change ( ± SD): −13.4 (1.5) vs. −7.2 (1.4), < 0.05; ES = −0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism.

Keywords

Autism Risperidone Behavioral symptoms Hyperactivity Irritability Safety 

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Gahan J. Pandina
    • 1
    • 3
  • Cynthia A. Bossie
    • 1
  • Eriene Youssef
    • 1
  • Young Zhu
    • 1
  • Fiona Dunbar
    • 2
  1. 1.Medical AffairsJanssen Pharmaceutica, Inc.TitusvilleUSA
  2. 2.Janssen-Ortho, Inc.TorontoCanada
  3. 3.CNS Clinical DevelopmentJanssen Medical Affairs, LLCTitusvilleUSA

Personalised recommendations